Abstract
Gene transfer and oncolytic viruses provide new therapeutic approaches for the treatment of hematologic malignancies. However, it is still too early to introduce gene delivery or oncolytic viruses into standard clinical protocol. It is very important to discuss the obstacles that gene transfer and oncolytic virotherapy face for the further clinical application for the treatment of hematologic malignancies, and updating the advances made to overcome them. The major concerns in this review include the approaches of the development of immuno-stimulatory gene transfer mediated-vaccination for leukemia therapy, RNAi-based therapy for leukemia and enhancement of sensitivity of target malignant cells to virotherapy and alteration of host immune response to favor oncolytic viruses. We conclude with a perspective on the future of the gene therapy and virotherapy for the treatment of hematologic malignancies, emphasizing the problems we should solve and the technological requirements for further clinical applications.
Keywords: Gene transfer, vaccination, RNAi, oncolytic viruses, hematologic malignancies.
Current Gene Therapy
Title:Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Volume: 16 Issue: 6
Author(s): Yingzhe Jiang, Bing Xia, Yizhuo Zhang*Wen Xu
Affiliation:
- Tianjin Medical University Cancer Institute and Hospital, 1 Huanhuxi Road, Hexi District, Tianjin 300060,China
Keywords: Gene transfer, vaccination, RNAi, oncolytic viruses, hematologic malignancies.
Abstract: Gene transfer and oncolytic viruses provide new therapeutic approaches for the treatment of hematologic malignancies. However, it is still too early to introduce gene delivery or oncolytic viruses into standard clinical protocol. It is very important to discuss the obstacles that gene transfer and oncolytic virotherapy face for the further clinical application for the treatment of hematologic malignancies, and updating the advances made to overcome them. The major concerns in this review include the approaches of the development of immuno-stimulatory gene transfer mediated-vaccination for leukemia therapy, RNAi-based therapy for leukemia and enhancement of sensitivity of target malignant cells to virotherapy and alteration of host immune response to favor oncolytic viruses. We conclude with a perspective on the future of the gene therapy and virotherapy for the treatment of hematologic malignancies, emphasizing the problems we should solve and the technological requirements for further clinical applications.
Export Options
About this article
Cite this article as:
Jiang Yingzhe, Xia Bing, Zhang Yizhuo*, Xu Wen, Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles, Current Gene Therapy 2016; 16 (6) . https://dx.doi.org/10.2174/1566523217666170215154755
DOI https://dx.doi.org/10.2174/1566523217666170215154755 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Cell Cycle Arrest and Apoptosis Induction Activity of Nitidine Chloride on Acute Myeloid Leukemia Cells
Medicinal Chemistry New Treatment Concepts In Diffuse Large B-Cell Lymphomas (DLBL): Chemotherapy and Biological Therapy
Reviews on Recent Clinical Trials DNA-drug Conjugates for Site-specific Delivery in Anti-cancer Therapy
Current Pharmacogenomics and Personalized Medicine Pathogenesis of HIV-Associated Non-Hodgkin Lymphoma
Current HIV Research T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets The Enzymology of Cytosolic Pyrimidine 5’-Nucleotidases: Functional Analysis and Physiopathological Implications.
Current Medicinal Chemistry The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design Pharmacological Interventions for the Prevention and Treatment of Kidney Injury Induced by Radiotherapy: Molecular Mechanisms and Clinical Perspectives
Current Molecular Pharmacology Kinases as Drug Discovery Targets in Hematologic Malignancies
Current Molecular Medicine Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Infrequent Infections in COPD
Current Respiratory Medicine Reviews The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Enhanced Floating and Intragastric Release of 5-Flourouracil through Sesame Oil Entrapped Gellan Composite Hydrogel Beads
Current Drug Therapy Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Antitumor Effect of Pomolic Acid in Acute Myeloid Leukemia Cells Involves Cell Death, Decreased Cell Growth and Topoisomerases Inhibition
Anti-Cancer Agents in Medicinal Chemistry HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design